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EGFR mutations are the best predictors of response to
EGFR kinase inhibitors in lung adenocarcinoma. We
evaluated two mutation-specific monoclonal antibod-
ies for the detection of EGFR mutations by immuno-
histochemistry (IHC), generated respectively against
the L858R mutant and the exon 19 mutant with the
common 15bp/5AA deletion. These two mutations ac-
count for approximately 90% of all EGFR mutations.
IHC staining performed on 218 paraffin-embedded
lung adenocarcinomas was assessed on a 0 to 3
scale, and positivity cutoffs of 1 and 2 were com-
pared. All cases were studied by standard molecular
methods for these two mutations, and selected cases
were also studied using higher sensitivity molecular
assays. The EGFR L858R mutant antibody showed a
sensitivity of 95% and a positive predictive value
(PPV) of 99% with a positivity cutoff of 1 and a
sensitivity of 76% and a PPV of 100% with a posi-
tivity cutoff of 2. The EGFR exon 19 mutant–spe-
cific antibody showed reduced sensitivity for exon
19 deletions other than 15bp. A positivity cutoff of
1 resulted in a sensitivity of 85% and a PPV of
99%, whereas a 2 cutoff gave a sensitivity of 67%
and a PPV of 100%. IHC with EGFR mutant–specific
antibodies could be used as a screen to identify
most candidates for EGFR inhibitors. (J Mol Diagn
2010, 12:169–176; DOI: 10.2353/jmoldx.2010.090140)
Somatic mutations within the tyrosine kinase domain of
EGFR are found in approximately 20% of lung adenocar-
cinomas and are the most reliable predictors of response
to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib
and gefitinib (Sharma et al, 2007).1 Multiple studies sup-
port that, in addition to their predictive value in treatment
selection, EGFR mutations are also prognostic for survival
benefit.2,3 Specifically, patients with these tumors survive
significantly longer on EGFR TKIs than with conventional
cytotoxic chemotherapy.4 EGFR-mutant lung adenocar-
cinomas also form a distinct clinically favorable biological
subset, regardless of EGFR TKI therapy.2 Mutated EGFR
is more often found in better differentiated adenocarcino-
mas with or without a bronchioloalveolar component.5,6 It is
virtually absent in other lung cancer subtypes except for
adenosquamous carcinoma.7,8
In-frame deletions in exon 19 and the exon 21 L858R
substitution are the most common EGFR mutations and,
combined, represent approximately 90% of all mutants.9
Analysis for common EGFR mutations is now performed
in many institutions to help direct treatment decisions.
Direct DNA sequencing is a common detection method
but has well-known sensitivity limitations depending on
the proportion of tumor cells present in the material avail-
able for DNA extraction. Other DNA-based methods have
been developed to address issues of sensitivity and turn-
around time associated with direct sequencing.10 How-
ever, the cost and complexity of molecular methods has
slowed their widespread implementation outside of
major academic centers and commercial laboratories
and drives the continued interest in less robust predictors
of response such EGFR copy number and conventional
immunohistochemistry (IHC) for total EGFR. IHC for total
EGFR is an especially poor substitute as it correlates
poorly or not at all with the presence of mutations.11,12
Another more challenging IHC strategy is to develop
antibodies that react only with the mutant form of a given
oncoprotein. Interest in this approach is driven by the fact
that IHC is a technology available to essentially all pa-
thology departments, can be automated, and can be
performed on samples where the number or proportion of
tumor cells poses challenges for molecular tests based
on bulk DNA extraction from tissue. Cell Signaling Tech-
nology has recently developed two mutant-specific anti-
bodies for IHC directed against the most common mutant
forms of EGFR: the 15-bp/5-aa deletion (E746_A750del) in
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exon 19 and the L858R point mutation in exon 21.13 In the
present study, we performed an independent evaluation of
these two antibodies on a large series of lung adenocarci-
nomas with molecular data available for EGFR mutation
status. We provide a careful assessment of putative false-
positive and false-negative results, including a detailed
analysis of how they relate to the molecular heterogeneity in
EGFR exon 19 deletions and we propose an algorithm for
their possible clinical implementation.
Materials and Methods
Tumor Samples
Two hundred eighteen lung adenocarcinoma samples,
procured at Memorial Sloan-Kettering Cancer Center un-
der IRB-approved protocols, between the years 1999
and 2008 were used for this study. The vast majority of
cases were classified as adenocarcinoma, mixed sub-
type. A total of 194 formalin-fixed paraffin-embedded
(FFPE) lung adenocarcinoma samples with available
EGFR molecular data were selected for tissue microarray
(TMA) construction. These included 18 EGFR L858R mu-
tants, 31 cases with EGFR exon 19 deletions (deletion sizes:
9 bp [n  4], 12 bp [n  1], 15 bp [n  20], 18 bp [n  3],
24 bp [n 3]), and 145 cases without either EGFRmutation.
The TMAs were constructed using triplicate 0.6-mm tissue
cores. Three cores from different areas were selected from
each tumor. Serial 4-um-thick tissue sections were freshly
cut from the TMAs for IHC. To more thoroughly evaluate the
mutation-specific IHC on tumors bearing a variety of exon
19 deletions, 24 tumors harboring less common exon 19
deletions (9, 12, 18, 24 bp) were identified, and unstained
slides were prepared using 4-um-thick tissue sections cut
directly from the FFPE tumor blocks.
DNA Extraction
Hematoxylin and eosin–stained sections of FFPE tissue
were reviewed for each sample to identify areas of tumor.
Table 1. Primers Listed by Assay
Fragment analysis
A1 EGFR-Ex19-FW1: 5-GCACCATCTCACAATTGCCAGTTA-3
A2 EGFR-Ex19-REV1: 5-Fam-AAAAGGTGGGCCTGAGGTTCA-3
B1 EGFR-Ex 19-FW2: 5-ATCCCAGAAGGTGAGAAAGATAAAATTC-3
B2 EGFR-Ex 19-REV2: 5-CCTGAGGTTCAGAGCCATGGA-3
B3 EGFR-Ex 19-REV3: 5-Fam-CCTGAGGTTCAGAGCCATGGA-3
C1 EGFR-Ex 19-FW4: 5-CCCAGCAATATCAGCCTTAGGTG-3
C2 EGFR-Ex 19-REV4: 5-CCACTAGAGCTGGAAAGGGAAAGA-3
D1 EGFR-Ex21-FW1: 5-CCTCACAGCAGGGTCTTCTCTGT-3
D2 EGFR-Ex21-REV1: 5-Fam-TCAGGAAAATGCTGGCTGACCTA-3
Sequenom Mass Spectrometry assay
E1 2573-FW 5-ACGTTGGATGACGTACTGGTGAAAACACCG-3
E2 2573- REV: 5-ACGTTGGATGTCTTTCTCTTCCGCACCCAG-3
E3 2573 extension primer-REV: 5-CACCCAGCAGTTTGGCC-3
Mass of extension primer: 5131.3 Da
Mass of extension product Call T: 5402.6 Da
Call G: 5378.5 Da
Table 2. Main Types of EGFR Exon 19 Deletions and Corresponding Amino Acid Sequences
Deletion size AA mutation AA sequence COSMIC (n  1531)
No mutation IKELREATSPKANKEIL
Del-9 L747_E749del IK. . .EATSPKANKEIL 6.4%
K745_L747del I. . .REATSPKANKEIL 0.2%
Del-12 E746_E749del IK. . . .ATSPKANKEIL 0.2%
Del-15 E746_A750del* IK. . . . .TSPKANKEIL 68.1%
L747_T751del IKE. . . . .SPKANKEIL 6.4%
K745_E749del I. . . . .ATSPKANKEIL 0.9%
A750_K754del IKELRE. . . . .ANKEIL 0.12%
Del-18 E746_T751del IK. . . . . .SPKANKEIL 0.7%
L747_S752del IKE. . . . . .PKANKEIL 2.4%
E746_S752X† IK. . . . . .XPKANKEIL 3.8%
L747_P753del IKE. . . . . . .KANKEIL 0.4%
L747_P753Q IKE. . . . . .QKANKEIL 1.1%
L747_P753S IKE. . . . . .SKANKEIL 6.7%
Del-24 E746_P753del IK. . . . . . .KANKEIL 0.4%
L747_K754del IKE. . . . . . .ANKEIL 0.12%
A750_K757del IKELRE. . . . . . .EIL 0.12%
T751_E758del IKELREA. . . . . . .IL 0.06%
S752_I759del IKELREAT. . . . . . .L 0.7%
The proportions among the 1531 Exon 19 deletion cases collected in COSMIC are indicated.
*15-bp deletion mutant used to generate the antibody.
†Complex deletion encoding novel amino acid (X), which varies between samples.
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Macrodissection was performed on corresponding un-
stained sections to ensure greater than 50% tumor vol-
ume for each case. Genomic DNA was extracted using
the QIAamp MiniKit kit (Qiagen) according to the manu-
facturer’s protocol.
Fragment Analysis for EGFR Exon 19 Deletion
Detection of the small in-frame deletions in exon 19 of
EGFR was performed by fragment analysis of fluores-
cently labeled PCR products as previously described.14
Briefly, a 207-bp genomic DNA fragment encompassing
the entire exon 19 was amplified using the primers A1
and A2 (Table 1). PCR products were subjected to cap-
illary electrophoresis on an ABI 3730 Genetic Analyzer
(Applied Biosystems, Foster City, CA). This assay can
detect an EGFR exon 19 deletion in as little as approxi-
mately 5% to 10% tumor cells in a given sample.14
Mutant-Enriched PCR Assay for EGFR Exon 19
Deletion
Cases showing discordant results between mutation-
specific IHC and the standard EGFR exon 19 mutational
assay described above were further studied using a
more sensitive mutant-enriched PCR assay.15 A 138-bp
genomic fragment of exon 19 was amplified with the
primers B1 and B2 (Table 1) for 17 cycles at 60°C. After
purification (QIAquick Purification kit, Qiagen), PCR prod-
ucts were subjected to restriction enzyme digestion by
the MseI enzyme (New England BioLabs) for 4 hours at
37°C. On an EGFR allele with an exon 19 deletion, the
restriction site would be absent yielding an undigested
PCR product. During a second round of amplification
(primers B1 and B3, 40 cycles at 60°C) only the mutant
and the undigested wild-type fragments are amplified.
The PCR products were analyzed by fragment analysis
on an ABI 3730 Genetic Analyzer (Applied Biosystems,
Foster City, CA). This assay has been reported to detect
an EGFR exon 19 deletion at a level of 0.1%.15
Sequencing for EGFR Exon 19 Deletion
Twenty cases with 15-bp and 17 cases with 18-bp Exon
19 deletion were also sequenced to characterize the
exact structure of the deletion. The PCR used primers C1
and C2 (35 cycles at 55°C). Direct sequencing was per-
formed on these purified PCR products on an ABI 3730
Genetic Analyzer (Applied Biosystems, Foster City, CA).
EGFR Exon 21 L858R Assay
This mutation was detected by a PCR-restriction fragment
length polymorphism assay (PCR-RFLP), based on a
Sau961 restriction site created by themutation 2573TGas
previously described.14 Briefly, a 222-bp genomic fragment
encompassing the entire exon 21 was amplified using prim-
ers D1 and D2 (Table 1). Digestion of the mutant PCR
product with Sau961 enzyme (New England BioLabs) gen-
erates a shorter 87-bp fragment. The digested fluorescently
labeled PCR products were analyzed by capillary electro-
phoresis on an ABI 3730 Genetic analyzer (Applied Biosys-
tems, Foster City, CA). The detection sensitivity of this assay
for the EGFR exon 21 L858R mutation is approximately 5%
to 10% tumor cells.14
EGFR Exon 21 L858R Mutation Analysis by
Mass Spectrometry
Cases with discordant mutation status between muta-
tion-specific IHC and the EGFR L858R PCR-RFLP as-
say were further studied by mass spectrometry-based
DNA analysis (Sequenom Inc, San Diego, CA), as de-
scribed elsewhere.16 Briefly, tumor DNA was subject to
a first PCR amplification following the recommenda-
tions of Sequenom (total volume: 5 l, 1.25 buffer,
1.625 mmol/L MgCl2, 500 mol/L dNTP, 100 nmol/L
from each primer, 0.5 U HotStar TaqDNA Polymerase
[Qiagen]) using primers E1 and E2 (Table 1). Alkaline
Phosphatase treatment was performed in a total vol-
ume of 2 l (final volume: 7 l), incubated at 37°C for
40 minutes and 85°C for 5 minutes. A single allele base
extension reaction was performed using the E3 primer
(Table 1). Two microliters of a solution containing 0.74
l ddH2O, 0.2 l Buffer (Sequenom Inc.), 0.1 l Ter-
Table 3. Prevalence of the Main EGFR Exon 19 Deletion
Sizes in the COSMIC Database (among 1531 Cases
with Exon 19 Deletion or Complex-Deletion), in
our TMA (among the 31 Cases with Exon 19
Deletion), and in our Clinical Data at MSKCC
during the Year 2008 (among the 107 Cases with
Exon 19 Deletion)
Size of EGFR
exon 19 deletion COSMIC*
MSKCC
TMA
MSKCC
clinical
data
9 bp 6.6% 12.9% 2.8%
12 bp 0.2% 3.2% 2%
15 bp 75.5% 64.5% 65%
18 bp 15.2% 9.7% 29%
24 bp 1.4% 9.7% 1%
*Total  98.9%. Some cases with very rare deletion sizes are not
included.
Table 4. Intensity of the Staining with Antibody to Total EGFR versus Mutation Status
Total EGFR 0 1 2 3
Wild-type (n  145) 86 (59.3%) 13 (8.9%) 25 (17.2%) 21 (14.5%)
L858R  (n  18) 7 (38.8%) 2 (11.1%) 3 (16.6%) 6 (33.3%)
Exon 19 del  (n  55) 15 (27.3%) 4 (7.3%) 11 (20%) 25 (45.6%)
P value for 2  2 table defined by staining 0-1 vs 2-3 and EGFR wild-type vs either mutant  0.0002 (Fisher exact test).
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mination Mix (Sequenom Inc.), 0.94 l of 7 mol/L
extension primer, and 0.02 l of Thermo Sequenase
(Sequenom Inc.) were added to the 7 l SAP (Shrimp
Alkaline Phosphatase) treated PCR products. Thermal
cycling was performed following the recommendations
of Sequenom. The detection sensitivity of this Seque-
nom assay for EGFR L858R is estimated to be 5%
tumor cells (not shown).
Mutation-Specific Antibodies and
Immunohistochemistry
Two rabbit monoclonal antibodies were kindly provided by
Cell Signaling, one with specificity for the exon 21 L858R
EGFR mutation and the other for the 15bp, E746-750 dele-
tion in exon 19.13 IHC was done manually using the follow-
ing protocol: after overnight incubation at 55°C and depar-
affinization, antigen retrieval was performed using EDTH pH
9 (Dako) for 30 minutes. Primary antibodies were applied
(dilution 1:100 for both antibodies) and the slides incubated
for 30 minutes. For detection, the EnVision kit (Dako) was
used following themanufacturer’s recommendations. Coun-
terstain was realized using hematoxylin, 4 minutes, and
Bluing reagent, 4 minutes.
IHC Scoring
Slides were scanned at low magnification and scored
based on cytoplasmic and/or membrane staining intensity
as follows: 0 no staining or faint staining intensity in10%
of tumor cells; 1  faint staining in 10% of tumor cells;
2  moderate staining; 3  strong staining. Triplicate
tumor tissue cores from the TMA were scored indepen-
dently, and a final composite grade was given for each
case. For TMA cases, a case was considered positive if at
least 1 core showed 2 or 3 staining or at least 2 cores
showed 1 staining. If only 1 of the 3 cores showed 1
staining, the case was scored as negative.
Control IHC staining for total EGFR protein and Cyto-
keratin AE1/AE3 were performed using the monoclonal
EGFR mouse antibody (Dilution 1:100, Clone 31G7,
Zymed Laboratories Inc.) and the anti-cytokeratin cock-
tail AE1/AE3 (Biogenex) according to the manufacturer’s
instructions. EGFR results were scored as follows: 0, no
membrane staining; 1, faint, partial membrane staining;
2, weak, complete membrane staining in 10% of tu-
mor cells; 3, intense complete membrane staining in
10% of tumor cells. A case was considered positive if at
least one core was scored 1, 2, or 3 (1 cutoff) or 2 or
3 (2 cutoff).
Figure 1. Immunohistochemistry staining of lung adenocarcinoma samples. A: Example of EGFR L858R mutant tumor. Cytokeratin AE1/AE3, total EGFR, and the
EGFR L858R mutant–specific antibody show a positive staining, whereas the EGFR Exon 19 deletion mutant–specific antibody is negative. B: Conversely, in a
tumor harboring the EGFR Exon 19 15-bp deletion, Cytokeratin AE1/AE3, Total EGFR, and the Exon 19 mutant–specific antibody show a positive staining whereas
the EGFR L858R mutant–specific antibody is negative.
Table 5. Summary of IHC Results on TMA Cases and
Mutation Status Based on PCR-Based Fragment
Analysis for EGFR Exon 19 Deletion
Exon 19 mutation analysis
(PCR-based fragment
analysis)
Mutation Mutation Total
A. 15-bp deletion cases only
IHC 20 2 22
IHC 0 161 161
Total 20 163 183
B. Exon 19 deletion cases
IHC 23 2 25
IHC 8 161 169
Total 31 163 194
Sensitivity in A is 100% (20/20). Sensitivity in B is 74.2% (23/31).
Specificity is 98.8% (161/163), considering true negatives as cases
lacking any type of exon 19 deletion.
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Results
Baseline EGFR Mutation Profile of Test Set
To provide a thorough evaluation of the sensitivity of
these two mutant-specific antibodies, the evaluation set
was enriched for EGFR mutant cases, in particular cases
with EGFR exon 19 deletions. Thus, EGFR mutations were
identified in 25.3% (49/194) of the cases present in the
TMA and in 33.5% (73/218) of all cases, based on frag-
ment analysis (compared with a prevalence of about 20%
among adenocarcinomas tested at our institution). The
EGFR L858R mutation was detected in 18 samples
(18/73, 23.7% of mutant cases), whereas 55 cases had
exon 19 deletions (55/73, 75.3% of mutant cases),
reflecting enrichment for non–15-bp EGFR exon 19
deletions. Deletion sizes were as follows: 9 bp (n  10),
12 bp (n  3), 15 bp (n  20), 18 bp (n  17), 24 bp
(n  5). The heterogeneity in the exact structure of
these in-frame deletions is shown in Table 2, based in
data from the COSMIC database. To obtain unbiased
data on the distribution of different types of EGFR exon
19 deletions, we also reviewed the cases collected in
the COSMIC database and we reviewed our in-house
prevalence based on 898 cases consecutively studied
during the year 2008 (Table 3). This confirmed that only
approximately 65% to 75% of EGFR exon 19 deletions
are 15 bp.
IHC Results
IHC was performed on the 194 samples on TMAs with a
panel of four antibodies that included the two EGFR
mutant–specific antibodies, total EGFR antibody, and cy-
tokeratin AE1/AE3 antibody as a control for tissue quality.
The 24 additional samples with less common exon 19
deletions were analyzed with total-EGFR and the exon 19
mutant–specific antibody.
Of the 218 samples, 39 cases (17.9%) were scored pos-
itive for the exon 19 EGFR mutant–specific antibody and 22
cases (10.1%) were scored positive for the EGFR L858R
mutant–specific antibody. Total EGFR was expressed (1
to 3) in 50.5% of all cases (110/218) and 69.7% of mutant
cases (51/73). Although it was statistically correlated with
the presence of mutation (P  0.0002; Table 4), it is impor-
tant to note that IHC for total EGFR is not usable as a test for
mutation status as it wouldmiss30%ofmutant cases and,
conversely, most strongly positive cases are not mutated
(Table 4). Cytokeratin was expressed in 100% of the sam-
ples, confirming the reactivity of the tissues for IHC. Figure
1A shows an example of positive staining for a case with
L858R mutation, whereas Figure 1B shows an example of
positive staining with the exon 19 mutant–specific antibody
in a case with a 15-bp deletion in EGFR exon 19. For both
mutant-specific antibodies, the staining was cytoplasmic
and membranous.
Correlation between Mutation-Specific IHC and
Mutation Status
All 20 cases with a 15-bp deletion in exon 19 by fragment
analysis were positive by IHC with the mutant-specific
antibody. Positive staining with the exon 19 mutant-spe-
cific antibody was also observed in two cases without
mutations (specificity  98.8%; Table 5). More sensitive
Table 6. Staining Intensity with the Exon 19 Deletion Mutant-Specific Antibody versus Exon 19 Deletion Size
0 1 2 3 Sensitivity
Exon 19 8 (80%) 1 (10%) 0 1 (10%) 20%
9-bp del (n  10)
Exon 19 1 (33.3%) 0 2 (66.7%) 0 67%
12-bp del (n  3)
Exon 19 0 2 (10%) 11 (55%) 7 (35%) 100%
15-bp del (n  20)
Exon 19 7 (41.2%) 6 (35.3%) 2 (11.8%) 2 (11.8%) 58.8%
18-bp del (n  17)
Exon 19 2 (40%) 1 (20%) 2 (40%) 0 60%
24-bp del (n  5)
False positive for A746-750 del Ab (n  2) — 2 (100%) — — —
Note: study group enriched for non–15-bp exon 19 deletions.
Table 7. Staining Intensity with the Exon 19 Deletion Mutant-Specific Antibody versus Sequence Results for the 15-bp and 18-bp
EGFR Exon 19 Deletion Mutants
Deletion size AA mutation AA sequence CDS mutation n IHC 0 IHC 1 IHC 2 IHC 3
Del-15 E746_A750del* IK. . . . . TSPKANKEIL Del 2235-2249 14 0 1 7 6
E746_A750del* IK. . . . . TSPKANKEIL Del 2236-2250 4 0 1 3 0
L747_T751del IKE. . . . . SPKANKEIL Del 2240-2254 1 0 0 1 0
NA 1 0 0 0 1
Del-18 L747_S752del IKE. . . . . . PKANKEIL Del 2239-2256 1 0 0 0 1
E746_S752V IK. . . . . . VPKANKEIL Del 2237-2255T (complex) 4 1 2 1 0
L747_P753Q IKE. . . . . . QKANKEIL Del 2239-2258CA (complex) 1 0 0 0 1
L747_P753S IKE. . . . . . SKANKEIL Del 2240-2257 10 5 4 1 0
NA 1 1 0 0 0
*Deletion mutant used for monoclonal antibody production.
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mutation assessment with mutant-enriched PCR in these
two cases failed to detect mutations (data not shown).
Of 35 cases with exon 19 deletions other than the
common 15-bp type, 48.6% stained positive with the
mutant-specific antibody with the following distribution:
20% (2/10) of 9-bp deletions, 67% (2/3) of 12-bp dele-
tions, 58.8% (10/17) of 18-bp deletions, and 60% (3/5) of
24-bp deletions (Table 5). Because of the low numbers of
cases available for some of these deletion sizes, the
percentages must be considered approximate; but it is
apparent that, overall, the sensitivity of this mutant-spe-
cific antibody is lower in non–15-bp deletion cases. In
contrast to the generally robust staining in cases with
15-bp deletions, in most of these non–15-bp deletion
cases, the staining quality was faint and heterogeneous
and only three cases (one del-9 and two del-18) had
strong and widespread staining (Table 6). To assess
whether staining intensity could be related to the exact
amino acid sequence of the deletion mutant, we se-
quenced all available 15-bp and 18-bp deletion cases;
Figure 2. Sequenom assay results for EGFR L858R in five cases with positive results by EGFR L858R
mutant–specific IHC but negative results with the EGFR L858R PCR-RFLP assay. The H3255 cell line
harboring the EGFR L858R mutation is a positive control, whereas the H358 cell line harboring the KRAS
34G/T mutation provides a negative control. A G call is visible, the mutant call (G) is visible at 5378.5 Da
and is indicated by an arrow. The germline call (T) is indicated by an asterisk. In tumor samples A and
B, only the T call is present and these cases were considered negative. In tumor samples C, D, and E, a
mutant peak is present (arrow), confirming the presence of the EGFR L858R mutation.
Table 8. Summary of IHC and Molecular Assays for the EGFR L858R Mutation
Mutation  Mutation  Total
IHC results versus mutation analysis by PCR-RFLP assay only
IHC 17 5 22
IHC 1 171 172
Total 18 176 194
IHC results versus combined results of PCR-RFLP and Sequenom assays
IHC 20 2 22
IHC 1 171 172
Total 21 173 194
Based on the combined results, the sensitivity is 95.2% (20/21) and the specificity is 98.8% (171/173).
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no simple relationship of the mutant amino acid se-
quence to the intensity of IHC staining was apparent
(Table 7). Notably, 15-bp deletions can generate the
common E746-750 deletion or, less commonly, the
L747_T751 deletion but both showed robust staining. Fi-
nally, to estimate the sensitivity of the exon 19 deletion
mutant-specific antibody in routine practice, we applied
the resulting deletion type-specific sensitivities to our
consecutive 2008 clinical testing data, which represent
an unbiased distribution of exon 19 deletion sizes. In the
year 2008, 898 adenocarcinomas were analyzed at
MSKCC for EGFR mutations, and this identified 107 cases
with exon 19 deletions, all with size information by our
standard fragment analysis-based clinical assay.11,14
Based on this modeling, we would project a sensitivity of
84.6% (90.5/107) and a specificity of 98.9% (782.1/791)
for this antibody based on the scoring used.
Regarding the EGFR L858R mutant cases, 17 of the 18
cases with an L858R mutation by PCR-RFLP were scored
positive with the L858R mutant specific antibody (94%,
Table 8). Five cases without the L858R mutation by PCR-
RFLP were also scored as positive (Table 8). Mass spec-
trometry–based genotyping (Sequenom) was performed
on these cases, which revealed an L858R mutation in
three of the five cases (Figure 2). Based on the combined
molecular data from the EGFR L858R PCR-RFLP assay
and the EGFR L858R Sequenom assay, IHC with the
EGFR L858R mutant–specific antibody showed a sensi-
tivity of 95.2% and a specificity of 98.8% (Table 8). Both
false positive cases presented only faint staining (1)
(Table 9). Therefore, changing the scoring to only cate-
gorize 2 and 3 cases as positive would raise the
positive predictive value of the IHC assay to 100% with a
minimal reduction in sensitivity.
Discussion
The diagnostic approach and management of patients
with lung adenocarcinoma has changed significantly with
the advent of TKIs targeting EGFR and the discovery of
activating EGFR mutations, which predict sensitivity to
these targeted drugs. As the determination of EGFR mu-
tation status becomes standard of practice in this patient
population, there is considerable interest in simple meth-
ods accessible to a wide range of laboratories. To ad-
dress this need, two new antibodies suitable for IHC have
been recently developed against the most common
EGFR mutations, 15bp exon 19 deletions and the L858R
mutation in exon 21.13
Our evaluation of these two antibodies confirms that
both perform remarkably well for the mutant proteins
against which they were raised, but that the clinical use-
fulness of one of them is reduced by the occurrence of
non–15-bp exon 19 deletions. Specifically, the EGFR
exon 19 mutant–specific antibody detects 100% of 15-bp
deletions, with a specificity of 98.8%. However, for non–
15-bp exon 19 deletion mutants, the sensitivity varied
depending on the deletion size, ranging from 20% to
67%. In the original series, Yu et al reported IHC results
on only two non–15-bp deletion cases, of which one was
positive by IHC.13 Importantly, non–15-bp exon 19 dele-
tion mutants account for 35% of exon 19 deletions in both
the COSMIC database and in our clinical testing experi-
ence. Based on this intrinsic limitation of its sensitivity for
exon 19 deletions, a negative result with this IHC assay
could not be used to exclude patients from molecular
testing. However, based on our specificity of 98.8%, a
positive result could obviate the need for confirmatory
molecular testing. Indeed, the positive predictive value of
2 to 3 staining is 100% in the present study. One
caveat to this prospect is that we found strong (3)
staining in only a minority of true positives; the more
frequent weak to moderate staining with this antibody
may present problems with interpretation in routine prac-
tice, causing many cases to be considered equivocal.
In contrast, we found the IHC assay for the L858R
mutation to be highly reliable and specific with sensitivity
and specificity similar to the initial report.13 If a more
stringent scoring is used (only 2 or 3 staining being
considered positive), the positive predictive value is
raised to 100% (with a sensitivity of 76%), and thus a
positive result could obviate the need for confirmatory
Figure 3. Possible algorithm for the use of EGFR mutation–specific antibod-
ies. Given its high PPV, IHC with EGFR mutant–specific antibodies could be
used as a first pass screening method to identify most lung cancer patients
eligible for EGFR-targeted therapy, thereby reducing the overall volume of
EGFR molecular testing by an estimated 10 to 15%.
Table 9. Intensity of Staining with the EGFR L858R Mutant-
Specific Antibody
0 1 2 3
L858R (n  21) 1 (4.8%) 4 (19%) 6 (28.6%) 10 (47.6%)
False positive
for L858R Ab
(n  2)
— 2 (100%) 0 0
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molecular testing and EGFR TKI therapy could be initi-
ated on the basis on the IHC result alone, whereas a
negative or equivocal result would trigger molecular test-
ing for EGFR L858R. Given our clinical testing experience
in which approximately 10% of lung adenocarcinomas
tested contain EGFR L858R, this suggests that for 100
adenocarcinomas stained, 7 or 8 would be scored pos-
itive (all expected to be true positives), and therefore the
molecular testing volume could be reduced by the same
proportion (7% to 8%). A similar scenario can be pro-
posed for the EGFR exon 19 deletion-specific antibody,
reducing the need for testing for that mutation by a similar
proportion. Based on these considerations, we present a
schema for the possible use of these antibodies (Figure
3), which could reduce the molecular testing volume for
EGFR mutations by about 15% while allowing faster treat-
ment initiation for approximately 75% of patients with
sensitizing EGFR mutations. The benefits of a testing
algorithm such as this should be balanced with the potential
delay caused by introducing another step before molecular
testing and with the cost tradeoff of running IHC on all cases
to reduce molecular testing by about 15%.
Aside from their potential to eliminate the need for
molecular testing in some cases, these antibodies may
also be implemented in other ways, for instance to guard
against molecular false-negatives attributable to exces-
sive admixed non-neoplastic elements. The IHC assays
may also prove useful in settings where molecular testing
may not be possible or reliable (ie, specimens with only a
few clusters of tumor cells, such as certain cytologies,
small biopsies, or metastatic lesions with tiny nests of
tumor cells where microdissection would be technically
challenging in routine practice). Both mutation-specific
antibodies present intriguing possibilities for research
applications, such as further exploration of issues of tu-
mor heterogeneity, analysis of morphologically normal
tissue adjacent to EGFR-mutant tumors, and others.
IHC has well-known advantages as a testing method,
but the major drawbacks include, in comparison with
molecular assays, generally higher interlaboratory vari-
ability in assay performance and higher interobserver
variability in assay interpretation. These aspects of IHC
lead to a higher risk of false positives than molecular
assays, unless staining is scored in a consistent and
rigorous fashion. A further consideration is that these IHC
antibodies obviously cannot detect other clinically rele-
vant mutations in EGFR, such as exon 18 G719 point
mutations, or exon 20 mutations, including the T790M
resistance mutation. In conclusion, the use of the EGFR
mutant–specific antibodies for IHC could be incorporated
into the routine IHC work-up of lung adenocarcinomas,
leading to more rapid initiation of EGFR TKI therapy and
a modest reduction in EGFR molecular testing volume.
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